Ambulatory Reflux Monitoring Guides Proton Pump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: A Clinical Trial

Published:September 16, 2020DOI:

      Background and Aims

      Proton pump inhibitor (PPI) therapy fails to provide adequate symptom control in up to 50% of patients with gastroesophageal reflux symptoms. Although a proportion do not require ongoing PPI therapy, a diagnostic approach to identify candidates appropriate for PPI cessation is not available. This study aimed to examine the clinical utility of prolonged wireless reflux monitoring to predict the ability to discontinue PPIs.


      This double-blinded clinical trial performed over 3 years at 2 centers enrolled adults with troublesome esophageal symptoms of heartburn, regurgitation, and/or chest pain and inadequate PPI response. Participants underwent prolonged wireless reflux monitoring (off PPIs for ≥7 days) and a 3-week PPI cessation intervention. Primary outcome was tolerance of PPI cessation (discontinued or resumed PPIs). Symptom burden was quantified using the Reflux Symptom Questionnaire electronic Diary (RESQ-eD).


      Of 128 enrolled, 100 participants met inclusion criteria (mean age, 48.6 years; 41 men). Thirty-four participants (34%) discontinued PPIs. The strongest predictor of PPI discontinuation was number of days with acid exposure time (AET) > 4.0% (odds ratio, 1.82; P < .001). Participants with 0 days of AET > 4.0% had a 10 times increased odds of discontinuing PPI than participants with 4 days of AET > 4.0%. Reduction in symptom burden was greater among the discontinued versus resumed PPI group (RESQ-eD, –43.7% vs –5.3%; P = .04).


      Among patients with typical reflux symptoms, inadequate PPI response, and absence of severe esophagitis, acid exposure on reflux monitoring predicted the ability to discontinue PPIs without symptom escalation. Upfront reflux monitoring off acid suppression can limit unnecessary PPI use and guide personalized management. (, Number: NCT03202537)


      Abbreviations used in this paper:

      AET (acid exposure time), GERD (gastroesophageal reflux disease), PPI (proton pump inhibitor), RESQ-eD (Reflux Symptom Questionnaire electronic Diary)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Peery A.F.
        • Crockett S.D.
        • Barritt A.S.
        • et al.
        Burden of gastrointestinal, liver, and pancreatic diseases in the United States.
        Gastroenterology. 2015; 149: 1731-1741
        • Vakil N.
        • van Zanten S.V.
        • Kahrilas P.
        • et al.
        The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.
        Am J Gastroenterol. 2006; 101 (quiz 1943): 1900-1920
        • Delshad S.D.
        • Almario C.V.
        • Chey W.D.
        • et al.
        Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms.
        Gastroenterology. 2020; 158: 1250-1261
        • Spechler S.J.
        • Hunter J.G.
        • Jones K.M.
        • et al.
        Randomized trial of medical versus surgical treatment for refractory heartburn.
        N Engl J Med. 2019; 381: 1513-1523
        • Kahrilas P.J.
        • Boeckxstaens G.
        • Smout A.J.
        Management of the patient with incomplete response to PPI therapy.
        Best Pract Res Clin Gastroenterol. 2013; 27: 401-414
        • Shaheen N.J.
        • Hansen R.A.
        • Morgan D.R.
        • et al.
        The burden of gastrointestinal and liver diseases, 2006.
        Am J Gastroenterol. 2006; 101: 2128-2138
        • Foundation A.
        American Gastroenterological Association—treating GERD.
        Choosing Wisely. 2012; (Available at: Accessed June 20, 2020.): 2020
        • Kurlander J.E.
        • Kennedy J.K.
        • Rubenstein J.H.
        • et al.
        Patients' perceptions of proton pump inhibitor risks and attempts at discontinuation: a national survey.
        Am J Gastroenterol. 2019; 114: 244-249
        • Kurlander J.E.
        • Rubenstein J.H.
        • Richardson C.R.
        • et al.
        Physicians' perceptions of proton pump inhibitor risks and recommendations to discontinue: a national survey.
        Am J Gastroenterol. 2020; 115: 689-696
        • Gyawali C.P.
        • Kahrilas P.J.
        • Savarino E.
        • et al.
        Modern diagnosis of GERD: the Lyon consensus.
        Gut. 2018; 67: 1351-1362
        • Abdallah J.
        • George N.
        • Yamasaki T.
        • et al.
        Most patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy also have functional esophageal disorders.
        Clin Gastroenterol Hepatol. 2019; 17: 1073-1080
        • Yadlapati R.
        • Tye M.
        • Keefer L.
        • et al.
        Psychosocial distress and quality of life impairment are associated with symptom severity in PPI non-responders with normal impedance-pH profiles.
        Am J Gastroenterol. 2018; 113: 31-38
        • Kahrilas P.J.
        • Bredenoord A.J.
        • Fox M.
        • et al.
        The Chicago classification of esophageal motility disorders, v3.0.
        Neurogastroenterol Motil. 2015; 27: 160-174
        • Dent J.
        • Vakil N.
        • Jones R.
        • et al.
        Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study.
        Gut. 2010; 59: 714-721
        • Jonasson C.
        • Wernersson B.
        • Hoff D.A.
        • et al.
        Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease.
        Aliment Pharmacol Ther. 2013; 37: 564-572
        • Vakil N.
        • Bjorck K.
        • Denison H.
        • et al.
        Validation of the reflux symptom questionnaire electronic diary in partial responders to proton pump inhibitor therapy.
        Clin Transl Gastroenterol. 2012; 3: e7
        • Patel A.
        • Sayuk G.S.
        • Gyawali C.P.
        Parameters on esophageal pH-impedance monitoring that predict outcomes of patients with gastroesophageal reflux disease.
        Clin Gastroenterol Hepatol. 2015; 13: 884-891
        • Afaneh C.
        • Zoghbi V.
        • Finnerty B.M.
        • et al.
        BRAVO esophageal pH monitoring: more cost-effective than empiric medical therapy for suspected gastroesophageal reflux.
        Surg Endosc. 2016; 30: 3454-3460
        • Lee W.C.
        • Yeh Y.C.
        • Lacy B.E.
        • et al.
        Timely confirmation of gastro-esophageal reflux disease via pH monitoring: estimating budget impact on managed care organizations.
        Curr Med Res Opin. 2008; 24: 1317-1327
        • Katz P.O.
        • Gerson L.B.
        • Vela M.F.
        Guidelines for the diagnosis and management of gastroesophageal reflux disease.
        Am J Gastroenterol. 2013; 108 (quiz 329): 308-328
        • Kahrilas P.J.
        • Shaheen N.J.
        • Vaezi M.F.
        • et al.
        American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease.
        Gastroenterology. 2008; 135: 1383-1391
        • Gyawali C.P.
        • Carlson D.C.
        • Chen J.W.
        • et al.
        Esophageal physiologic testing american college of gastroenterology clinical guideline.
        Am J Gastroenterol. 2020; 115: 1412-1428
        • Singh S.
        • Garg S.K.
        • Singh P.P.
        • et al.
        Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis.
        Gut. 2014; 63: 1229-1237
        • Kahrilas P.J.
        • Boeckxstaens G.
        Failure of reflux inhibitors in clinical trials: bad drugs or wrong patients?.
        Gut. 2012; 61: 1501-1509
        • Shaheen N.J.
        • Falk G.W.
        • Iyer P.G.
        • et al.
        ACG clinical guideline: diagnosis and management of Barrett's esophagus.
        Am J Gastroenterol. 2016; 111 (quiz 51): 30-50
        • Yadlapati R.
        • Pandolfino J.E.
        Personalized approach in the work-up and management of gastroesophageal reflux disease.
        Gastrointest Endosc Clin North Am. 2020; 30: 227-238
        • Riehl M.E.
        • Chen J.W.
        The proton pump inhibitor nonresponder: a behavioral approach to improvement and wellness.
        Curr Gastroenterol Rep. 2018; 20: 34
        • Dickman R.
        • Maradey-Romero C.
        • Fass R.
        The role of pain modulators in esophageal disorders—no pain no gain.
        Neurogastroenterol Motil. 2014; 26: 603-610
        • Cannon 3rd, R.O.
        • Quyyumi A.A.
        • Mincemoyer R.
        • et al.
        Imipramine in patients with chest pain despite normal coronary angiograms.
        N Engl J Med. 1994; 330: 1411-1417
        • You L.Q.
        • Liu J.
        • Jia L.
        • et al.
        Effect of low-dose amitriptyline on globus pharyngeus and its side effects.
        World J Gastroenterol. 2013; 19: 7455-7460
        • Roman S.
        • Keefer L.
        • Imam H.
        • et al.
        Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux.
        Neurogastroenterol Motil. 2015; 27: 1667-1674
        • Riehl M.E.
        • Kinsinger S.
        • Kahrilas P.J.
        • et al.
        Role of a health psychologist in the management of functional esophageal complaints.
        Dis Esophagus. 2015; 28: 428-436
        • Gawron A.J.
        • Bell R.
        • Abu Dayyeh B.K.
        • et al.
        Surgical and endoscopic management options for patients with GERD based on proton pump inhibitor symptom response: recommendations from an expert U.S. panel.
        Gastrointest Endosc. 2020; 92: 78-87
        • Gyawali C.P.
        • Fass R.
        Management of gastroesophageal reflux disease.
        Gastroenterology. 2018; 154: 302-318
        • Yadlapati R.
        • Pandolfino J.E.
        • Alexeeva O.
        • et al.
        The Reflux Improvement and Monitoring (TRIM) program is associated with symptom improvement and weight reduction for patients with obesity and gastroesophageal reflux disease.
        Am J Gastroenterol. 2018; 113: 23-30
        • Dunbar K.B.
        • Agoston A.T.
        • Odze R.D.
        • et al.
        Association of acute gastroesophageal reflux disease with esophageal histologic changes.
        JAMA. 2016; 315: 2104-2112